<DOC>
	<DOCNO>NCT00551642</DOCNO>
	<brief_summary>The purpose study assess safety efficacy inhale nitric oxide reduce risk chronic lung disease pre-term infant respiratory distress , assess long-term effect therapy development child 7 year clinical follow-up .</brief_summary>
	<brief_title>Safety Efficacy Study Nitric Oxide Inhalation Chronic Lung Disease Premature Babies</brief_title>
	<detailed_description>Although effect inhale Nitric Oxide pulmonary vascular tone well-described relevant term infant persistent pulmonary hypertension , pathophysiology respiratory failure preterm infant may quite different . Chronic lung disease ( CLD ) represent final pathway heterogeneous group pulmonary disorder infancy usually start neonatal period . CLD commonly occur preterm ( &lt; 30 week gestational age ( GA ) infant birth weight le 1,500 g , especially preterm ( &lt; 26 wks GA ) birth weight less 1,000 g , treat respiratory distress syndrome ( RDS ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Inborn preterm infant 24+0 weeks28+6 day week gestational age ( define first trim ultrasound available base last menstrual period ) require use surfactant within 24 hour birth ( either prophylactically , sign develop respiratory distress ) , require use continuous positive airway pressure ( CPAP ) ( fraction inspire oxygen concentration ( FiO2 ) ≥ 0.30 mean airway pressure ≥ 4cm water ( H2O ) ) within 24 hour birth order maintain oxygen saturation ( SpO2 ) ≥ 85 % . Informed consent guardian . Outborn infant . Infants ≥ 29 week gestational age . Infants require FiO2 &gt; 0.5 maintain SpO2 &gt; 85 % , sufficient mean airway pressure ( e.g. , &gt; 8 cm H2O control mechanical ventilation ( CMV ) ) order achieve adequate chest inflation ( 89 rib Chest Xray ) two hour proper administration exogenous surfactant . Any suspect congenital heart disease patent ductus arteriosus atrial septal defect . Any infant severe bleed coagulation abnormality highrisk diathesis , e.g. , platelet &lt; 50,000/mm³ , fibrinogen &lt; 0.5 g/L , clot factor &lt; 10 % . Any infant decision make provide full treatment , e.g. , chromosomal abnormality , severe multiple abnormality , severe birth asphyxia , etc . Use another investigational drug device active study period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>26 Hours</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Preemie , Inhaled Nitric Oxide</keyword>
</DOC>